525 related articles for article (PubMed ID: 11421935)
41. [Clinical study on bronchial asthma and leukotriene antagonists].
Yokoyama A
Nihon Naika Gakkai Zasshi; 2004 Dec; 93(12):2656-61. PubMed ID: 15658499
[No Abstract] [Full Text] [Related]
42. Leukotriene modifiers.
Hallstrand TS; Henderson WR
Med Clin North Am; 2002 Sep; 86(5):1009-33, vi. PubMed ID: 12428543
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic advances: leukotriene antagonists for the treatment of asthma.
Misson J; Clark W; Kendall MJ
J Clin Pharm Ther; 1999 Feb; 24(1):17-22. PubMed ID: 10319903
[TBL] [Abstract][Full Text] [Related]
44. Anti-leukotrienes: here to stay?
Barnes PJ
Curr Opin Pharmacol; 2003 Jun; 3(3):257-63. PubMed ID: 12810189
[TBL] [Abstract][Full Text] [Related]
45. Functional characteristics of cysteinyl-leukotriene receptor subtypes.
Bäck M
Life Sci; 2002 Jun; 71(6):611-22. PubMed ID: 12072150
[TBL] [Abstract][Full Text] [Related]
46. Leukotriene E
Lazarinis N; Bood J; Gomez C; Kolmert J; Lantz AS; Gyllfors P; Davis A; Wheelock CE; Dahlén SE; Dahlén B
J Allergy Clin Immunol; 2018 Oct; 142(4):1080-1089. PubMed ID: 29518425
[TBL] [Abstract][Full Text] [Related]
47. [New developments in asthma therapy: how do individual leukotriene antagonists work?].
Wagener M
Praxis (Bern 1994); 1998 Feb; 87(8):271-5. PubMed ID: 9542455
[TBL] [Abstract][Full Text] [Related]
48. Leukotriene modifiers: novel therapeutic opportunities in asthma.
Buccellati C; Fumagalli F; Viappiani S; Folco G
Farmaco; 2002 Mar; 57(3):235-42. PubMed ID: 11989802
[TBL] [Abstract][Full Text] [Related]
49. Asthma pharmacotherapy: an update on leukotriene treatments.
Trinh HKT; Lee SH; Cao TBT; Park HS
Expert Rev Respir Med; 2019 Dec; 13(12):1169-1178. PubMed ID: 31544544
[No Abstract] [Full Text] [Related]
50. [Leukotriene modifiers in the treatment of asthma].
Alvarez J
Rev Alerg Mex; 1999; 46(3):72-7. PubMed ID: 10425884
[TBL] [Abstract][Full Text] [Related]
51. Leukotriene-receptor antagonists. Role in asthma management.
D'Urzo AD; Chapman KR
Can Fam Physician; 2000 Apr; 46():872-9. PubMed ID: 10790819
[TBL] [Abstract][Full Text] [Related]
52. Montelukast: more than a cysteinyl leukotriene receptor antagonist?
Tintinger GR; Feldman C; Theron AJ; Anderson R
ScientificWorldJournal; 2010 Dec; 10():2403-13. PubMed ID: 21170491
[TBL] [Abstract][Full Text] [Related]
53. Antileukotriene agents in asthma: the dart that kills the elephant?
Renzi PM
CMAJ; 1999 Jan; 160(2):217-23. PubMed ID: 9951445
[TBL] [Abstract][Full Text] [Related]
54. Regulation of leukotrienes in the management of asthma: biology and clinical therapy.
Leff AR
Annu Rev Med; 2001; 52():1-14. PubMed ID: 11160764
[TBL] [Abstract][Full Text] [Related]
55. Leukotriene receptor antagonists in asthma therapy.
Peters SP
J Allergy Clin Immunol; 2003 Jan; 111(1 Suppl):S62-70. PubMed ID: 12532087
[TBL] [Abstract][Full Text] [Related]
56. Montelukast: its role in the treatment of childhood asthma.
Harmanci K
Ther Clin Risk Manag; 2007 Oct; 3(5):885-92. PubMed ID: 18473012
[TBL] [Abstract][Full Text] [Related]
57. Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot study.
Gao JM; Cai F; Peng M; Ma Y; Wang B
Chin Med J (Engl); 2013 Jun; 126(12):2229-34. PubMed ID: 23786930
[TBL] [Abstract][Full Text] [Related]
58. Effect of cysteinyl leukotriene receptor antagonist on CD11b and CD23 expression in asthmatic children.
Gagro A; Aberle N; Rabatić S; Ajduk J; Jelacić J; Dekaris D
Clin Exp Allergy; 2004 Jun; 34(6):939-44. PubMed ID: 15196283
[TBL] [Abstract][Full Text] [Related]
59. Cysteinyl leukotriene-dependent interleukin-5 production leading to eosinophilia during late asthmatic response in guinea-pigs.
Nabe T; Yamashita K; Miura M; Kawai T; Kohno S
Clin Exp Allergy; 2002 Apr; 32(4):633-40. PubMed ID: 11972613
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
